Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 1:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,143 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MR Imaging Techniques - 2 Clear all
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 12, 2026, 1:50 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

NCT03952585
View directory record Official record
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Active, not recruiting Not applicable Interventional Results available

PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer

NCT01737619
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, Malignant Mixed Mesodermal (Mullerian) Tumor
Interventions
Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis, Lymph Node Mapping, Lymphadenectomy, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

NCT01036581
View directory record Official record
Conditions
Drug Abuse, Nicotine Dependence
Interventions
MagPro X100 Magnetic Stimulator, Transcranial Rotating Magnetic Stimulator, Magnetom Prisma Fit 3T Scanner
Device
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

NCT06311227
View directory record Official record
Conditions
Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Aventura, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Terminated Phase 1 Interventional Results available

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

NCT04751383
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

NCT05045027
View directory record Official record
Conditions
Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
Interventions
Biospecimen Collection, Diagnostic Imaging, Magnetic Resonance Imaging
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 12, 2026, 1:50 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

NCT07095205
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Nicotine transdermal patch, PET Scan with [18F] VAT
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 12, 2026, 1:50 PM EDT
Completed Phase 2 Interventional

CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

NCT04727242
View directory record Official record
Conditions
LMS - Leiomyosarcoma, Uterine Leiomyosarcoma
Interventions
Gemcitabine, Dacarbazine, Cytoreductive Surgery, Functional Assessment of Cancer Therapy (FACT) G questionnaire, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan, Gadolinium
Drug · Procedure · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Not listed Phase 2 Interventional

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

NCT00083083
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Drug · Genetic · Procedure + 1 more
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
46
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 12, 2026, 1:50 PM EDT
Not yet recruiting Phase 2 Interventional

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT07612007
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Not yet recruiting Not applicable Interventional

A Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA Trial

NCT07331077
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
Interventions
Accelerometry, Aerobic Exercise, Electronic Health Record Review, Functional Magnetic Resonance Imaging, Gait Assessment Test, Health Education, Interview, Neurocognitive Assessment, Physical Performance Testing, Questionnaire Administration
Procedure · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analyzing Retinal Microanatomy in ROP

NCT02887157
View directory record Official record
Conditions
Retinopathy of Prematurity, Neurodevelopmental Disorders, Macular Edema
Interventions
Swept Source OCT, Magnetic Resonance Imaging, Scavenged blood collection
Device · Other
Lead sponsor
Duke University
Other
Eligibility
30 Weeks and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
4
States / cities
Gainesville, Florida • St Louis, Missouri • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 12, 2026, 1:50 PM EDT
Recruiting Phase 3 Interventional

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

NCT07200830
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring, Computed Tomography, Bone Scan, PSMA PET Scan, MRI, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
129
States / cities
Anchorage, Alaska • Bakersfield, California • Irvine, California + 106 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Long COVID-19 [11C]CPPC Study

NCT06223971
View directory record Official record
Conditions
COVID Long-Haul
Interventions
[11C]CPPC Injection
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

NCT04166409
View directory record Official record
Conditions
Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions
Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
124
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Terminated Phase 2 Interventional Results available

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

NCT00659334
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Ferumoxtran-10 (Combidex), Neurosurgery
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
5 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 12, 2026, 1:50 PM EDT
Completed No phase listed Observational

Objective Brain Function Assessment of mTBI/Concussion in High School Athletes

NCT02661633
View directory record Official record
Conditions
Brain Injuries, Traumatic, Concussion, Brain, Concussion, Mild, Concussion, Intermediate, Concussion, Severe
Interventions
BrainScope Ahead 200iD, Advanced MRI Neuroimaging
Device
Lead sponsor
BrainScope Company, Inc.
Industry
Eligibility
13 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Fayetteville, Arkansas • Bethesda, Maryland • East Lansing, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 12, 2026, 1:50 PM EDT
Completed No phase listed Observational

Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI

NCT03656250
View directory record Official record
Conditions
Nasopharyngeal Cancer
Interventions
PET/CT scans
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 12, 2026, 1:50 PM EDT
Active, not recruiting Phase 2 Interventional

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

NCT06112847
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 12, 2026, 1:50 PM EDT
Completed Not applicable Interventional Results available

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

NCT00660543
View directory record Official record
Conditions
Adult Brain Glioblastoma
Interventions
Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 12, 2026, 1:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass

NCT02236754
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
18 F-FP-DTBZ, PET Scanning
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 12, 2026, 1:50 PM EDT
Recruiting Phase 1 Interventional

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

NCT06672705
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 12, 2026, 1:50 PM EDT